BrainEver
French tech company | Builders Republic
About
Clinical-stage biotech developing disease-modifying therapies for neurodegenerative disorders based on homeoproteins, signaling proteins that stay active in adult neurons — its lead program targets Parkinson's disease, with a pipeline extending to ALS and age-related eye diseases such as macular degeneration and glaucoma.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series B
- Founded
- 2015
- City
- PARIS 12
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 33 M€ raised since 2020
Funding rounds
- Series B — 2025